{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:03Z","timestamp":1787003703422,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["CH\/16\/2\/32089)."],"award-info":[{"award-number":["CH\/16\/2\/32089)."]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/16\/47\/32190"],"award-info":[{"award-number":["FS\/16\/47\/32190"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["17\/YH\/0300"],"award-info":[{"award-number":["17\/YH\/0300"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["18\/YH\/0168"],"award-info":[{"award-number":["18\/YH\/0168"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["18\/YH\/0168"],"award-info":[{"award-number":["18\/YH\/0168"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/16\/47\/32190"],"award-info":[{"award-number":["FS\/16\/47\/32190"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Romanian society of cardiology","award":["95\/01.09.2020"],"award-info":[{"award-number":["95\/01.09.2020"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["221690\/Z\/20\/Z"],"award-info":[{"award-number":["221690\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","award":["RP-2017-08-ST2-007"],"award-info":[{"award-number":["RP-2017-08-ST2-007"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metformin is an antihyperglycemic used to treat type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease. We explored the association between metformin use and cardiovascular magnetic resonance (CMR) derived stress myocardial blood flow (MBF), myocardial perfusion reserve (MPR) and major adverse cardiovascular events (MACE; all cause death, MI, stroke, heart failure hospitalisation and coronary revascularisation) in patients with T2DM. Multi-centre study of patients with T2DM, and healthy controls, underwent quantitative myocardial perfusion CMR using an artificial intelligence supported process. Multivariable regression analysis, and cox proportional hazard models of propensity score weighted patients quantified associations between metformin use, MBF, MPR, all cause death and MACE. Analysis included 572 patients with T2DM (68% prescribed metformin) with median follow-up 851 days (IQR 935\u2009\u2212\u2009765). Metformin use was associated with an increase of MPR of 0.12 [0.08\u20130.40],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004. There were 82 MACE events (14.3%) including 25 (4.4%) deaths of which 16 were in those not prescribed metformin (8.7%), compared to 9 in patients prescribed metformin (2.3%): adjusted hazard ratio 0.24 (95% CI 0.08\u20130.70,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009). MACE events were similar between groups. This multicentre, inverse probability weighting propensity score analysis study showed that in patients with T2DM, metformin use is associated with higher MPR and improved all cause survival.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-77280-2","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T10:43:45Z","timestamp":1731062625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metformin associates with higher myocardial perfusion reserve and survival in type 2 diabetes mellitus patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Noor","family":"Sharrack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher D.","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav S.","family":"Gulsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A. E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L.","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmaine","family":"Thirunavukarasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylem","family":"Levelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry P.","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Munyombwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Plein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"77280_CR1","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph, J. J. et al. Comprehensive Management of Cardiovascular Risk factors for adults with type 2 diabetes: a Scientific Statement from the American Heart Association. Circulation. 145, e722\u2013e759. https:\/\/doi.org\/10.1161\/CIR.0000000000001040 (2022).","journal-title":"Circulation"},{"key":"77280_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2019","unstructured":"Cosentino, F. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486 (2019). (2020).","journal-title":"Eur. Heart J."},{"key":"77280_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/diacare.2.2.120","volume":"2","author":"WB Kannel","year":"1979","unstructured":"Kannel, W. B. & McGee, D. L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 2, 120\u2013126. https:\/\/doi.org\/10.2337\/diacare.2.2.120 (1979).","journal-title":"Diabetes Care"},{"key":"77280_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D. & Diabetes Other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16, 434\u2013444. https:\/\/doi.org\/10.2337\/diacare.16.2.434 (1993).","journal-title":"Diabetes Care"},{"key":"77280_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2019","unstructured":"Buse, J. B. et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43 487\u2013493 https:\/\/doi.org\/10.2337\/dci19-0066 (2020).","journal-title":"Diabetes Care"},{"key":"77280_CR6","unstructured":"In Type 2 Diabetes in Adults: Management National Institute for Health and Care Excellence: Guidelines (2015)."},{"key":"77280_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2012.10.001","volume":"104","author":"International Diabetes Federation Guideline Development","year":"2014","unstructured":"International Diabetes Federation Guideline Development. Global guideline for type 2 diabetes. Diabetes Res. Clin. Pract. 104, 1\u201352. https:\/\/doi.org\/10.1016\/j.diabres.2012.10.001 (2014).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"77280_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4158\/EP161682.CS","volume":"23","author":"AJ Garber","year":"2017","unstructured":"Garber, A. J. et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary. Endocr. Pract. 23, 207\u2013238. https:\/\/doi.org\/10.4158\/EP161682.CS (2017).","journal-title":"Endocr. Pract."},{"key":"77280_CR9","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 352, 854\u2013865 (1998).","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"77280_CR10","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","volume":"25","author":"JA Johnson","year":"2002","unstructured":"Johnson, J. A., Majumdar, S. R., Simpson, S. H. & Toth, E. L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25, 2244\u20132248. https:\/\/doi.org\/10.2337\/diacare.25.12.2244 (2002).","journal-title":"Diabetes Care"},{"key":"77280_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/s0735-1097(01)01129-9","volume":"37","author":"KJ Mather","year":"2001","unstructured":"Mather, K. J., Verma, S. & Anderson, T. J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 37, 1344\u20131350. https:\/\/doi.org\/10.1016\/s0735-1097(01)01129-9 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"77280_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2796.2005.01531.x","volume":"258","author":"C Vitale","year":"2005","unstructured":"Vitale, C. et al. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 258, 250\u2013256. https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01531.x (2005).","journal-title":"J. Intern. Med."},{"key":"77280_CR13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2006.04.088","volume":"48","author":"S Jadhav","year":"2006","unstructured":"Jadhav, S. et al. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: A randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 48, 956\u2013963. https:\/\/doi.org\/10.1016\/j.jacc.2006.04.088 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"77280_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.amjcard.2004.02.028","volume":"93","author":"J Kao","year":"2004","unstructured":"Kao, J. et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am. J. Cardiol. 93, 1347\u20131350. https:\/\/doi.org\/10.1016\/j.amjcard.2004.02.028 (2004).","journal-title":"Am. J. Cardiol."},{"key":"77280_CR15","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 373, 1765\u20131772. https:\/\/doi.org\/10.1016\/S0140-6736(09)60697-8 (2009).","journal-title":"Lancet"},{"key":"77280_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12968-017-0397-8","volume":"19","author":"E Levelt","year":"2017","unstructured":"Levelt, E. et al. Adenosine stress CMR T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus without obstructive coronary artery disease. J. Cardiovasc. Magn. Reson. 19, 81. https:\/\/doi.org\/10.1186\/s12968-017-0397-8 (2017).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"77280_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/ehjci\/jeu142","volume":"15","author":"AM Larghat","year":"2014","unstructured":"Larghat, A. M. et al. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: A cardiovascular magnetic resonance study. Eur. Heart J. Cardiovasc. Imaging 15, 1368\u20131376. https:\/\/doi.org\/10.1093\/ehjci\/jeu142 (2014).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"77280_CR18","doi-asserted-by":"publisher","unstructured":"Kramer, C. M. et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J. Cardiovasc. Magn. Reson. 22 https:\/\/doi.org\/10.1186\/s12968-020-00607-1 (2020).","DOI":"10.1186\/s12968-020-00607-1"},{"key":"77280_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12968-017-0355-5","volume":"19","author":"P Kellman","year":"2017","unstructured":"Kellman, P. et al. Myocardial perfusion cardiovascular magnetic resonance: Optimized dual sequence and reconstruction for quantification. J. Cardiovasc. Magn. Reson. 19, 43. https:\/\/doi.org\/10.1186\/s12968-017-0355-5 (2017).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"77280_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin, P. C. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. Stat. Med. 33, 1242\u20131258. https:\/\/doi.org\/10.1002\/sim.5984 (2014).","journal-title":"Stat. Med."},{"key":"77280_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/oby.2003.174","volume":"11","author":"AE Caballero","year":"2003","unstructured":"Caballero, A. E. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes. Res. 11, 1278\u20131289. https:\/\/doi.org\/10.1038\/oby.2003.174 (2003).","journal-title":"Obes. Res."},{"key":"77280_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","volume":"137","author":"D Kirpichnikov","year":"2002","unstructured":"Kirpichnikov, D., McFarlane, S. I. & Sowers, J. R. Metformin: An update. Ann. Intern. Med. 137, 25\u201333. https:\/\/doi.org\/10.7326\/0003-4819-137-1-200207020-00009 (2002).","journal-title":"Ann. Intern. Med."},{"key":"77280_CR23","first-page":"249","volume":"79","author":"E Alexanderson-Rosas","year":"2009","unstructured":"Alexanderson-Rosas, E. et al. [Effects of the combined treatment with Metformin\/Glimepiride on endothelial function of patients with type 2 diabetes mellitus. A positron emission tomography (PET) evaluation study]. Arch. Cardiol. Mex. 79, 249\u2013256 (2009).","journal-title":"Arch. Cardiol. Mex"},{"key":"77280_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-017-0525-7","volume":"16","author":"J van Haare","year":"2017","unstructured":"van Haare, J. et al. Metformin and sulodexide restore cardiac microvascular perfusion capacity in diet-induced obese rats. Cardiovasc. Diabetol. 16, 47. https:\/\/doi.org\/10.1186\/s12933-017-0525-7 (2017).","journal-title":"Cardiovasc. Diabetol."},{"key":"77280_CR25","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1007\/s00125-010-1910-x","volume":"53","author":"LN Broekhuizen","year":"2010","unstructured":"Broekhuizen, L. N. et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53, 2646\u20132655. https:\/\/doi.org\/10.1007\/s00125-010-1910-x (2010).","journal-title":"Diabetologia"},{"key":"77280_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jcmg.2020.10.015","volume":"14","author":"H Rahman","year":"2021","unstructured":"Rahman, H. et al. High-resolution cardiac magnetic resonance imaging techniques for the identification of coronary microvascular dysfunction. JACC Cardiovasc. Imaging. 14, 978\u2013986. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.015 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"77280_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","volume":"18","author":"Y Han","year":"2019","unstructured":"Han, Y. et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis. Cardiovasc. Diabetol. 18, 96. https:\/\/doi.org\/10.1186\/s12933-019-0900-7 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"77280_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40265-021-01665-0","volume":"82","author":"T Li","year":"2022","unstructured":"Li, T. et al. Association of metformin with the mortality and incidence of cardiovascular events in patients with pre-existing cardiovascular diseases. Drugs 82, 311\u2013322. https:\/\/doi.org\/10.1007\/s40265-021-01665-0 (2022).","journal-title":"Drugs"},{"key":"77280_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","volume":"7","author":"S Gandini","year":"2014","unstructured":"Gandini, S. et al. Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila). 7, 867\u2013885. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0424 (2014).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"77280_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","volume":"66","author":"DR Morales","year":"2015","unstructured":"Morales, D. R. & Morris, A. D. Metformin in cancer treatment and prevention. Annu. Rev. Med. 66, 17\u201329. https:\/\/doi.org\/10.1146\/annurev-med-062613-093128 (2015).","journal-title":"Annu. Rev. Med."},{"key":"77280_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.4254\/wjh.v7.i12.1652","volume":"7","author":"A Bhat","year":"2015","unstructured":"Bhat, A., Sebastiani, G. & Bhat, M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J. Hepatol. 7, 1652\u20131659. https:\/\/doi.org\/10.4254\/wjh.v7.i12.1652 (2015).","journal-title":"World J. Hepatol."},{"key":"77280_CR32","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/dom.13362","volume":"20","author":"P Breining","year":"2018","unstructured":"Breining, P. et al. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes Obes. Metab. 20, 2264\u20132273. https:\/\/doi.org\/10.1111\/dom.13362 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"77280_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-8587(13)70125-6","volume":"2","author":"C Patrone","year":"2014","unstructured":"Patrone, C., Eriksson, O. & Lindholm, D. Diabetes drugs and neurological disorders: New views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2, 256\u2013262. https:\/\/doi.org\/10.1016\/S2213-8587(13)70125-6 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"77280_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","volume":"94","author":"E Neven","year":"2018","unstructured":"Neven, E. et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int. 94, 102\u2013113. https:\/\/doi.org\/10.1016\/j.kint.2018.01.027 (2018).","journal-title":"Kidney Int."},{"key":"77280_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-023-01817-4","volume":"22","author":"P Mone","year":"2023","unstructured":"Mone, P. et al. Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: Preliminary results from the LEOPARDESS Study. Cardiovasc. Diabetol. 22, 94. https:\/\/doi.org\/10.1186\/s12933-023-01817-4 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"77280_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.23087","author":"G Santulli","year":"2024","unstructured":"Santulli, G. et al. Prediabetes increases the risk of frailty in older adults with prefrail hypertension: Beneficial effects of metformin. Hypertension https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23087 (2024).","journal-title":"Hypertension"},{"key":"77280_CR37","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.18632\/aging.202858","volume":"13","author":"Q Chen","year":"2021","unstructured":"Chen, Q., Thompson, J., Hu, Y. & Lesnefsky, E. J. Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function. Aging (Albany NY). 13, 7828\u20137845. https:\/\/doi.org\/10.18632\/aging.202858 (2021).","journal-title":"Aging (Albany NY)"},{"key":"77280_CR38","doi-asserted-by":"publisher","unstructured":"Dziubak, A., Wojcicka, G., Wojtak, A. & Beltowski, J. Metabolic effects of metformin in the failing heart. Int. J. Mol. Sci. 19 https:\/\/doi.org\/10.3390\/ijms19102869 (2018).","DOI":"10.3390\/ijms19102869"},{"key":"77280_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","volume":"104","author":"S Gundewar","year":"2009","unstructured":"Gundewar, S. et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 104, 403\u2013411. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.190918 (2009).","journal-title":"Circ. Res."},{"key":"77280_CR40","doi-asserted-by":"publisher","first-page":"7694","DOI":"10.3390\/ijms13067694","volume":"13","author":"G Barreto-Torres","year":"2012","unstructured":"Barreto-Torres, G., Parodi-Rullan, R. & Javadov, S. The role of PPARalpha in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia\/reperfusion in rats. Int. J. Mol. Sci. 13, 7694\u20137709. https:\/\/doi.org\/10.3390\/ijms13067694 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"77280_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","volume":"603","author":"T Ma","year":"2022","unstructured":"Ma, T. et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 603, 159\u2013165. https:\/\/doi.org\/10.1038\/s41586-022-04431-8 (2022).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77280-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T11:03:51Z","timestamp":1731063831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77280"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77280-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"10 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the patients provided written informed consent for their inclusion and approval was provided by the respective local ethics committees from each site and conducted in accordance with the Declaration of Helsinki. Leeds data was obtained with ethical approval obtained by Leeds Research Ethics Committee (REC), Leeds, United Kingdom, reference 17\/YH\/0300, 18\/YH\/0168 and 18\/YH\/01900. Barts data used ethical approval from East of England, Cambridge Central Research Ethics Committee, United Kingdom, REC 14\/EE\/0007. Royal Free data was provided by the University College London\/University College London Hospital Joint Committees on the Ethics of Human Research for recruitment at Royal Free Hospital (REC reference 07\/H0715\/101), United Kingdom. Leicester data ethical approval was provided by the UK Health Research Authority Research Ethics Committee (reference 17\/WM\/0192).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication was obtained from all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"27280"}}